Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer
January 27th 2023The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
Ribociclib Data Show Reduced Mortality Risk in HR+/HER2- Advanced Breast Cancer
May 9th 2022Officials from Novartis emphasized that the ribociclib-fulvestrant combination is the only one in the CDK4/6 inhibitor class to demonstrate an overall survival benefit when used in a first-line setting among postmenopausal women.
Read More
Living Life With Metastatic Breast Cancer From a Male Perspective
October 6th 2020In this episode of Managed Care Cast, we speak with a male patient with breast cancer who was diagnosed with metastatic disease in 2016 about how he lives his life and what he wants people to know about this rare cancer.
Listen
Contributor: Helping Women of Color Achieve a Healthier Future
April 27th 2022To achieve health equity, experts from CVS Health discuss why we must invest in programs that improve access to health care for historically marginalized communities, address social determinants, boost health education, increase representation in all levels of health care delivery, widen access to clinical trial research, and more.
Read More
Breast MRI Linked to Greater Downstream Service Use, Costs vs Mammography
April 20th 2022This investigation focused on use of additional services and incidence of new diagnoses among women who underwent a breast cancer screening MRI—having a low or average risk of the cancer—compared with a matched cohort who underwent mammography.
Read More
2 Clarke Drive
Cranbury, NJ 08512